Skip to main content

TENOFOVIR DISOPROXIL/ EMTRICITABINE/ EFAVIRENZ Mylan (Alphapharm Pty Ltd)

Product name
TENOFOVIR DISOPROXIL/ EMTRICITABINE/ EFAVIRENZ Mylan
Date registered
Evaluation commenced
Decision date
Approval time
200 working days (255)
Active ingredients
Tenofovir disoproxil, emtricitabine, efavirenz
Registration type
New generic medicine
Indication
TENOFOVIR DISOPROXIL, EMTRICITABINE, EFAVIRENZ Mylan (tablets) is indicated for the treatment of HIV infected adults over the age of 18 years.

Help us improve the Therapeutic Goods Administration site